Diagnosis of sepsis with inflammatory biomarkers, cytokines, endothelial functional markers from SIRS patients

Mingming Xue, PhD*, Feixiang Xu, PhD, Yilin Yang, PhD, Zhengang Tao, PhD, Yumei Chen, PhD, Sheng Wang, PhD, Jun Yin, PhD, Min Min, PhD, Dongwei Shi, PhD, Chenling Yao, Zhenju Song

Abstract

**Background** Sepsis is a life-threatening illness with a challenging diagnosis. Rapid detection is the key to successful treatment of sepsis. To investigate diagnostic value, the plasma protein profiles of inflammatory biomarkers, cytokines, and endothelial functional markers were compared between healthy controls, SIRS, and septic patients.

**Methods** The plasma protein profiles were performed by Luminex Assay in a cohort of 50 SIRS patients, 82 septic patients and 25 healthy controls. Fourteen plasma proteins were analyzed in the same cohort: IL-1β, IL-6, IL-8, IL-10, CCL-2, VEGF, VEGF-C, VEGFR2, CD62E, CD62P, MFG-E8, ICAM-1, TFPI, Urokinase.

**Result** IL-2R, IL-6, IL-8, IL-10, CCL-2, ICAM-1, and Urokinase were significantly higher in sepsis patients than SIRS patients. VEGF, IL-1β, CD62E, CD62P, MFG-E8, and TFPI have no statistical difference. VEGF-C, VEGFR2 were significantly different in SIRS patients than sepsis patients. Urokinase, ICAM-1, and VEGFR2 were significantly different between sepsis group and SIRS group. The AUCs of Urokinase, ICAM-1, and VEGFR2 and the combination for the diagnosis of sepsis were 0.650, 0.688, 0.643, and 0.741, respectively.

**Conclusions** Most patients have the higher level of several cytokines and developed endothelial cell injury in the initial phase of sepsis, Urokinase, ICAM-1, and VEGFR2 may be useful to evaluate severity and prognosis of sepsis patients.

**Abbreviations:** ALP = alkaline phosphatase, ALT = glutamic-pyruvic transaminase, APACHEII = Acute Physiology And Chronic Health Evaluation II, APTT = activated partial thromboplastin time, ARDS = acute respiratory distress syndrome, AST = aspartate transaminase, AUROC:area under receiver operating characteristic, CCL-2/JE/MCP-1:monocyte chemotactic protein-1, CRP = C reactive protein, EMRS = electronic medical record system, FIB = fibrinogen, ICAM-1/CD54:intercellular adhesion molecule-1, IL-1β = Interleukin-1β, IL-10:Interleukin-10, IL-6:Interleukin-6, IL-8/CXCL8:Interleukin-8, INR = international normalized ratio, LDH = lactate dehydrogenase, mmol/L = millimole per liter, PLT = platelet count, proBNP = pro-N-terminal brain natriuretic peptide, PT = prothrombin time, ROC:receiver operating characteristic, SIRS = Systemic Inflammatory Response Syndrome, SOFA = Sequential Organ Failure Assessment score, TFPI = tissue factor pathway inhibitor, TT = thrombin time, uPA/u-Plasminogen Activator/ Urokinase, VCAM = vascular cell adhesion molecule, VEGF = vascular endothelial growth factor, VEGF-C:vascular endothelial growth factor-C, VEGFR2/KDR/Fk-1:vascular endothelial growth factor receptor 2, WBC = white blood cell count.

**Keywords:** cytokines, endothelial functional markers, inflammatory biomarkers, sepsis, SIRS

---

1. Introduction

Sepsis as a systemic inflammatory response syndrome (SIRS) caused by an infection can cause damage to the body tissues and organs themselves and can even be life-threatening. It is difficult to recognize patients with sepsis because without a specific clinical signs. Despite the great improvement in detect this disease, septic patients are a heterogeneous group and their condition has been very difficult to recognize especially in the early stages.

The definition of sepsis which involves SIRS plus proof or suspicion of infection, could be very broad and it includes a large number of patients who do not develop sepsis. At the same time, the transition from SIRS to sepsis and septic shock develops over time differently in various patients so that even the progression of serious disease could be unrecognized until it reaches the late stage. Additionally, early clinical signs of sepsis are variable and nonspecific. Therefore, considering these limitations in diagnosis of sepsis and the importance of reducing mortality and cost of care, the evaluation system of sepsis should be developed. Early sepsis is easily misdiagnosed as SIRS, leading to delayed treatment. Therefore, more specific markers are required for the diagnosis of sepsis.
The aim of this study was to investigate the importance and difference of several biomarkers to distinguish patients with sepsis from those with infectious SIRS.

2. Methods

2.1. Patients and study design

A retrospective study was carried out in the emergency department of Zhongshan Hospital, Fudan University, Shanghai, China. Fifty SIRS patients, 82 septic patients, and 25 healthy controls on admission from October 2019 to September 2020 were enrolled in this study. According to the ACCP/SCCM (American College of Chest Physicians/Society of Critical Care Medicine), in all patients who met two or more criteria for SIRS (body temperature body temperature >38 or <36°C, heart rate >90 beats/min, respiratory rate >20 breath/min or pCO2 <4.3 kPa, white blood cell count >12.0 x 10^9/L or <4.0 x 10^9/L, or >10% immature forms) were enrolled. The diagnosis of sepsis referred to The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), namely, suspected infection with a Sequential Organ Failure Assessment (SOFA) score ≥2.

The exclusion criteria were as follows:
1. age <18 years;
2. immune system disease;
3. malignancy;
4. hematological disease;
5. thrombotic disease;
6. chronic liver disease; and
7. chronic renal failure requiring hemodialysis.

The study was approved by the Institutional Research Ethics Committee of Zhongshan Hospital, Fudan University (No: 2006-23). All of the cases and controls were enrolled consecutively. Informed consent was waived because of the retrospective nature of this study.

2.2. Severity and outcome assessment

The Acute Physiology and Chronic Health Evaluation (APACHE) II score was assessed at the enrollment of the patients with sepsis. The APACHE II score is designed to assess the severity of critically ill patients based on physiologic measurements, age and previous health status and is used for the prediction of outcome in critically ill patients. The Sequential Organ Failure Assessment (SOFA) score was assessed at the same time points that blood samples were taken. The SOFA is a scoring system composed of six organ systems (comprising the respiratory, coagulation, hepatic, cardiovascular, renal, and nervous systems) and can be used for the evaluation of organ failure and prognosis.

2.3. Data collection

Patient baseline data, including age, sex, site of infection, APACHE II, and SOFA scores, were collected from the Electronic Medical Record System (EMRS). Underlying medical history was also obtained, including ischemic heart disease, chronic heart failure, chronic obstructive pulmonary disease, cerebrovascular accident, and diabetes mellitus. The levels of coagulation indices (prothrombin time [PT], thrombin time [TT], activated partial thromboplastin time [APTT], fibrinogen [FIB] and D-dimer, platelet count [PLT], and lactate were collected. Blood coagulation, including those for PT, TT, APTT, and FIB, was assayed using the CS-2100i automatic coagulation analyzer (Sysmex).

2.4. Biomarker measurement

After admission to the emergency department, 2 to 3mL venous blood was drawn from septic and SIRS control patients upon enrollment and added to a tube containing sodium citrate (BD Vacutainer with sodium citrate anticoagulant, UK). The blood samples were centrifuged at 3000 rpm at 4°C for 10 minutes, and then the supernatant was stored at −80°C for use. The frozen plasma samples were thawed just before use, by immersion in a water bath at 37°C for 5 minutes.

Preparation of antibody conjugated LumineSTM beads. Coupling LumineX MagPlex-COOH beads (Bio-Rad; Hercules, CA) to monoclonal antibodies was based on the procedures outlined in the X-MAP Cookbook. All primary antibodies that contained amine containing additives or preservations were cleaned using Micro Bio-Spin 6 Tris chromatography columns (Bio-Rad; Hercules, CA) according to the manufacture’s instructions. Conjugation of antibodies to LumineXSTM MagPlex-COOH beads was performed using the Bio-Rad bead making kit, and conjugated beads were quantified using a TC20 cell counter.

2.5. Statistical analysis

Normally distributed continuous variables were expressed as the means±standard deviations, and abnormally distributed continuous variables were expressed as medians (25th and 75th quartiles). Student’s t test or one-way analysis of variance was used to compare normally distributed continuous variables. Kruskal–Wallis one-way analysis or Mann–Whitney U test was utilized to compare nonnormally distributed continuous variables. Categorical data were expressed as numbers (percentages) and compared with Pearson’s chi-square test or Fisher’s exact test when appropriate. Receiver operating characteristic (ROC) curves were constructed, and the areas under the ROC curves (AUCs) were determined. A multivariate logistic regression model based on a forward stepwise method was used to identify the abnormal parameters. The hazard ratios with 95% confidence intervals (CIs) to show markers of all-cause mortality. All statistical analyses were two-tailed, and the significance level was set to P < .05. Statistical analyses were performed using SPSS (version 22.0, SPSS, Chicago, IL).

3. Results

3.1. Demographic characteristics of the study population

One hundred thirty-two SIRS patients and 25 healthy controls were consecutively enrolled in this study, 82 of SIRS patients were diagnosed with sepsis. The baseline characteristics of the study population were shown in Table 1. Of the patients with sepsis, 33 were men and 49 were women, and the mortality rate of these patients was 30.5%. There was no significant difference in age and sex between control, SIRS and septic patients. The median of APACHE II and SOFA scores had significantly difference between three groups. The most common sources of infection in sepsis group were respiratory system (28/82, 34.1%), urinary tract infection (22/82, 26.8%), liver abscess (18/82, 22.0%), abdominal infection (12/82, 14.6%), soft tissue infection (2/82, 2.4%), central nervous system infection (4/82, 4.9%), and other
Etiology of infections in sepsis group were: Gram-negative bacterial infections in 21 (26%), Gram-positive bacterial infections in 45 (54.9%), fungal/viral infections in 11 (13.4%) and unknown infection in 5 (6.1%).

3.2. Laboratory measurements of septic patients and SIRS patients at enrollment

We analyzed the laboratory findings between healthy control, sepsis and SIRS patients. We found that sepsis patients had significantly higher levels of WBC, neutrophil percent (N%), C-reactive (CRP), procalcitonin (PCT), lactate, and lymphocyte percent (L%) (Table 2). The count of platelets were significantly decreased in the sepsis group compared with control and SIRS group. The level of Hb in septic patients was lower than SIRS group, but there was not statistically significant. The levels of PT, APTT, and INR were significantly increased in sepsis patients compared with SIRS patients throughout the study period. There was no significantly difference in the level of TT, Fib, and D-Dimer. The level of LDH was significantly higher in sepsis group. The level of BUN was significantly higher in sepsis group, but there were no significance between creatinine and glomerular filtration rate (GFR). The level of proBNP was significantly higher in sepsis group. The level of cTnT was no significance between two groups. The level of CK-MM was significantly higher in sepsis group, but there were no significance between CK, CK-MB, and myoglobin.

3.3. Plasma levels of cytokines and endothelial functional markers at enrollment

The levels of IL-2R, IL-6, IL-8, IL-10, and MCP-1 were significantly increased in sepsis patients compared with SIRS patients throughout the study period in Table 3. There was no significantly difference in the level of IL-1β. The levels of VEGF-C and VEGFR-2 were decreased in sepsis patients compared with SIRS patients. Figure S1 shows that the level of VEGF has no significantly difference (Figure S1, Supplemental Digital Content, http://links.lww.com/MD/G606, which demonstrates the plasma levels of VEGF at enrollment between different groups). The level of ICAM-1 was significantly increased in sepsis patients compared with SIRS patients throughout the study period. The levels of u-Plasminogen Activator were significantly increased in sepsis patients compared with SIRS patients. There were no significantly difference in the levels of E-Selection, P-Selection, MFG-E8, and TFPI (Fig. 1).

3.4. Plasma levels of Urokinase, ICAM-1, VEGFR2, and combined for sepsis diagnosis

We performed multivariate logistic regression analysis among SIRS and sepsis patient, found that the levels of Urokinase, ICAM-1, and VEGFR2 were independent predictors for diagnosis after multivatiate analysis (Tables 4 and 5). The ORs of the Urokinase, ICAM-1, and VEGFR2 were 1.001 (1.000–1.003, P = .038), 1.002 (1.001–1.003, P = .045), 0.857 (0.768–0.956, P = .006), respectively. The evaluation of each marker to diagnosis sepsis was carried out via ROC analysis. ROC curve analysis was used to evaluate the value of different biomarkers to identify the disease status. The AUCs of Urokinase, ICAM-1, VEGF-C, and combined scores were 0.65, 0.688, 0.345, and 0.745, respectively. These values exceeded those for the other markers (Fig. 2).

4. Discussion

The ability to diagnose for sepsis is vitally important for patients’ outcomes. In the current study, the results indicated that:
Characteristics of cytokines and endothelial functional markers between different groups.

|                      | Healthy control (N = 25) | SIRS (N = 50) | Sepsis (N = 82) | P     |
|----------------------|--------------------------|--------------|----------------|-------|
| TNFa                 | 5.61 ± 1.61              | 26.04 ± 27.6 | 32.61 ± 81.78  | 0.664 |
| IL-1β (pg/mL)        | 12.41 ± 7.12             | 30.55 ± 42.61| 48.37 ± 95.71  | 0.216 |
| IL-2R (pg/mL)        | 419.53 ± 132.00          | 980.33 ± 409.61| 1407.47 ± 1102.19 | 0.006 |
| IL-6 (pg/mL)         | 6.04 ± 1.51              | 21.33 ± 17.73| 321.78 ± 1179.01| 0.024 |
| CXCL8/LR-3 (pg/mL)   | 23.04 ± 12.78            | 57.54 ± 116.9 | 306.62 ± 1117.76 | 0.049 |
| IL-10 (pg/mL)        | 6.87 ± 1.59              | 8.97 ± 6.84  | 20.76 ± 27.30  | <0.001|
| CCL-2/MCP-1 (pg/mL)  | 323.91 ± 54.02           | 423.4 ± 196.79| 735.54 ± 801.27 | 0.001 |
| VEGF (pg/mL)         | 79.96 ± 48.38            | 232.31 ± 167.00| 228.31 ± 265.23 | 0.924 |
| VEGF-C (pg/mL)       | 2.05 ± 0.55              | 2.00 ± 2.57 | 1.33 ± 0.57    | 0.025 |
| VEGFR2/kdr/Flik-1 (ng/mL) | 16.08 ± 2.84     | 13.92 ± 3.75 | 12.02 ± 3.64 | 0.005 |
| CD62E/C-E-Selection (ng/mL) | 29.34 ± 7.42 | 69.13 ± 36.5 | 77.08 ± 51.34 | 0.302 |
| CD62P/P-Selection (ng/mL) | 37.46 ± 8.09 | 41.21 ± 16.26 | 40.52 ± 15.14 | 0.805 |
| MGFR-E8 (ng/mL)      | 1.02 ± 0.39              | 1.62 ± 1.12  | 1.77 ± 0.99    | 0.443 |
| ICAM-1/CD54 (ng/mL)  | 416.66 ± 372.98          | 456.08 ± 264.56| 613.85 ± 265.49 | 0.001 |
| TFP (ng/mL)          | 16.84 ± 6.80             | 17.03 ± 4.72 | 20.25 ± 22.4   | 0.233 |
| Urokinase/α-Plasminogen Activator (uPA) (pg/mL) | 989.31 ± 183.75 | 1030.2 ± 275.22 | 1432.08 ± 192.42 | 0.045 |

1. Compared healthy controls and SIRS patients, septic patients had higher body temperatures, SOFA and APACHE II scores, and higher mortality.

2. We found that sepsis patients had significantly higher levels of WBC, Neutrophil percent, C-reactive (CRP), procalcitonin (PCT), lactate, lymphocyte percent, LDH, BUN, and proBNP. The count of platelets were significantly decreased in the sepsis group. The cytokine levels of IL-2R, IL-6, IL-10, and MCP-1 were significantly increased in sepsis patients compared with SIRS patients.

3. The levels of VEGF-C and VEGFR-2 were decreased in sepsis patients compared with SIRS patients. The level of ICAM-1 and u-Plasminogen Activator was significantly increased in sepsis patients compared with SIRS patients throughout the study period.

4. The AUCs of Urokinase, ICAM-1, VEGFR2, and combined scores were 0.650, 0.688, 0.643, and 0.741, respectively, indicating that Urokinase, ICAM-1, VEGFR2 could be the helpful factors for diagnosis in patients with sepsis.
It is increasingly recognized that sepsis therapy should not be limited to antimicrobial treatment. Instead, great health benefits may be realized by correcting the dysregulated immune response which underlies septic shock pathobiology.[11] Endothelial inflammation is a hallmark of sepsis[12–14] and leads to shock and MODS.[15,16] Several cytokines produced by activated endothelial have effects on the endothelia themselves and immune cells that interact with them: IL-6 has a role in angiogenesis.[17–20] Endothelial activation induces expression of ICAM-1, which is involved in sepsis pathogenesis and is markers of end-organ failure, morbidity, and mortality in severe sepsis.[21]

It is well known that endothelial activation is crucial in sepsis. During inflammatory states, ICAM-1 was a vascular endothelial surface receptor that allows for leukocytes and other inflammatory cells to bind and translocate into local tissue. Up-to-date, many studies showed that its level is increased in patients with sepsis. Our study indicated that the level of ICAM-1 and u-Plasminogen Activator was significantly increased in sepsis patients. Bavunoglu et al found that ICAM-1 had a high sensitivity (99%) and specificity (99%) for detecting sepsis.[22] Furthermore, multiple mouse models have shown that ICAM-1 knockout mice with severe forms of sepsis have lower mortality rates. A study has demonstrated that ICAM-1 level in the sepsis and the SIRS groups was significantly higher than that in the control group, and it is also higher in the sepsis group than in the SIRS group.[23] Another study also confirmed that high levels of serum ICAM-1 was associated with the development of MOF.[22] Obregon et al provides an interesting insight that ICAM-1 seem to crucial in the pathogenesis and may potentially work as a complementary tool for the physician in the diagnosis of sepsis.[24]

In this study, we found the levels of VEGF-C and VEGFR2 were decreased in sepsis patients compared with SIRS patients, and VEGFR2 has diagnostic value in sepsis patients. Vascular endothelial growth factor (VEGF) is crucial for vascular

| Variables | OR (95% CI) | P |
|-----------|-------------|---|
| IL-6      | 1.024 (1.006, 1.043) | .011 |
| IL-10     | 1.077 (1.016, 1.142) | .013 |
| CCL2/MCP-1| 1.001 (1.002, 1.002) | .02 |
| IL-2      | 1.003 (1.002, 1.004) | .021 |
| VEGF      | 1 (0.998, 1.001) | .923 |
| VEGF-C    | 0.436 (0.239, 0.796) | .007 |
| VEGFR2    | 0.868 (0.785, 0.961) | .006 |
| ICAM-1    | 1.002 (1.001, 1.004) | .002 |
| Urokinase | 1.002 (1.001, 1.003) | .004 |
| TFPI      | 1.012 (0.987, 1.037) | .34 |
development and stimulate the formation of blood vessels. The over-production of VEGF is associated with acute inflammation. Two receptor tyrosine kinase (RTK) receptors have been identified for VEGF (VEGFR1 and VEGFR2).[25] VEGFR2 is regarded as the main signalling receptor for angiogenesis, proliferation, and permeability.[26] VEGFR2 knockout mice fail to develop blood islands or organised blood vessels resulting in early death.[27] VEGFR2 also has a prosurvival function with anti-apoptotic effects on human umbilical venous endothelial cells (HUVECs).[28] The VEGF family is involved in vascular permeability regulation in sepsis, via yet incompletely understood mechanisms.[29] Aslan et al have shown that after LPS injection in mouse, VEGFR2 expression declined sharply in the lung.[30] Our study confirmed that the plasma level of VEGFR2 decreases associated with severity of infection.

The plasminogen activator (PA) system, an essential system in cell differentiation, migration and reconstruction, mainly contains urokinase-type plasminogen activator (uPA), uPA receptor (uPAR), tissue type plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), and PAI-2.[31] uPA commonly is expressed in neutrophils, monocytes, macrophages, and activated T cells, and is reported to be capable of regulating inflammation, immune responses, and human endothelial cell cancers in several inflammatory diseases.[32–34] Several studies also report that uPA is beneficial in inflammation by activating T cells and may act as an antibiotic agent in mice model infected with staphylococcus aureus.[32–36] Nonetheless, very limited studies report the impact of uPA in sepsis. Our study confirmed that the plasma levels of u-Plasminogen Activator (uPA) were significantly increased in sepsis patients compared with SIRS patients, and uPA has diagnostic value in sepsis patients. The study by Yang and colleagues examined 81 patients with septic shock due to pneumonia, along with 20 patients in sepsis patients. The study by Yang and colleagues examined 81 patients with septic shock due to pneumonia, along with 20 patients in sepsis patients.

Table 5

| Variables   | OR (95% CI)     | P     |
|-------------|-----------------|-------|
| VEGFR2      | 0.857 (0.768, 0.956) | .006  |
| ICAM-1      | 1.002 (1.001, 1.003) | .045  |
| Urokinase   | 1.001 (1.003, 1.003) | .038  |
| Combined    | 1.012 (0.987, 1.037) | .994  |

that the endothelial functional markers of Urokinase, ICAM-1 and VEGFR2 were the potential diagnostic tools in patients with suspected sepsis. Monitoring of these markers could raise the possibility to distinguish between patients with sepsis and those with infectious SIRS, leading to early intervention for patients with sepsis.

5. Conclusions

In conclusion, there are many changes of clinical findings, laboratory parameters and cytokines during sepsis. We found

References

[1] Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801–10.
[2] Stephan AH, Montoya RL, Aluisio AR. Sepsis and septic shock in low- and middle-income countries. Surg Infect (Larchmt) 2020;21:571–8.
[3] Salomão R, Ferreira BL, Salomão MC, et al. Sepsis: evolving concepts and challenges. Braz J Med Biol Res 2019;52:e8595.
[4] Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign guidelines committee including the pediatric subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165–228.
[5] Mirijello A, Tosoni A, On behalf of The Internal Medicine Sepsis Study Group. New strategies for treatment of sepsis. Medicina (Kaunas) 2020;56:527.
[6] Biron BM, Ayala A, Lomas-Neira JL. Biomarkers for Sepsis: What Is and What Might Be?. Vol 10s4. 2015;Biomarker Insights London, England: SAGE Publications Sage UK, BMI.S29519.
[7] Zhang Z, Hong Y. Development of a novel score for the prediction of hospital mortality in patients with severe sepsis: the use of electronic healthcare records with LASSO regression. Oncotarget 2017;8:49637–45.
[8] Raith EP, Udy AA, Bailey M, et al. Prognostic accuracy of the SOFA Score, SIRS Criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA 2017;317:290–300.
[9] Funk D, Sebat F, Kumar A. A systems approach to the early recognition and rapid administration of best practice therapy in sepsis and septic shock. Curr Opin Crit Care 2009;15:301–7.
[10] McLymont N, Glover GW. Scoring systems for the characterization of sepsis and associated outcomes. Ann Transl Med 2016;4:527–1527.
[11] Mitchell M, Levy AR, Phillips GS, et al. Surviving sepsis campaign: association between performance metrics and outcomes in a 7.5-year study. Crit Care Med 2014;40:1623–33.
[12] Vallet B. Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction? Crit Care 2003;7:130–8.
[13] Sandrone K, Yann B, Anne DA, et al. Endothelium-dependent vasodilatation in the skin microcirculation of patients with septic shock. Shock 2003;19:274–80.
[14] Davis JS, Yeo TW, Thomas JH, et al. Sepsis-associated microvascular dysfunction measured by peripheral arterial tonometry: an observational study. Crit Care 2009;13:R155.
[15] Ciro C, Katalin M, Gábor O, et al. Endothelial dysfunction is a potential contributor to multiple organ failure and mortality in aged mice subjected to septic shock: preclinical studies in a murine model of cecal ligation and puncture. Crit Care 2014;18:511.
[16] Duffy MJ, Mullan BA, Craig TR, et al. Impaired endothelium-dependent vasodilatation is a novel predictor of mortality in intensive care. Crit Care Med 2011;39:629–35.
[17] Motro B, Itin A, Sachs L, et al. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 1990;87:3092–6.

[18] Colotta F, Sciacca FL, Sironi M, et al. Expression of monocyte chemoattractant protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994;144:975–85.

[19] Pierrakos C, Vincent J-L. Sepsis biomarkers: a review. Crit Care 2010;14:R15.

[20] Inge G, Andrei P, Anca R, et al. Biomarkers of inflammation and the etiology of sepsis. Biochem Soc Trans 2020;48:1–14.

[21] Zonneveld R, Martinelli R, Shapiro NI, et al. Soluble adhesion molecules as markers for sepsis and the potential pathophysiological discrepancy in neonates, children and adults. Crit Care 2014;18:204.

[22] Amalakuhan B, Habib SA, Mangat M, et al. Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. Cytokine 2016;88:267–73.

[23] Hao Ou, Xianzhong Xiao, Yu Jiang, et al. Expression of microRNA-23b in patients with sepsis and its effect on leukocytes and the expression of E-selectin and ICAM-1. Exp Ther Med. 16:4707–4711.

[24] Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 2010;87:262–71.

[25] Aslan A, van Meurs M, Mower J, et al. Organ-specific differences in endothelial permeability-regulating molecular responses in mouse and human Sepsis. Shock 2017;48:69–77.

[26] Peng Y, Gao M, Jiang Y, et al. Angiogenesis inhibitor endostatin protects mice with sepsis from multiple organ dysfunction syndrome. Shock 2015;44:357–64.

[27] Sugio K, Mishima H, Kodama A, et al. Regulatory mechanism of collagen degradation by keratocytes and corneal inflammation: the role of urokinase-type plasminogen activator. Cornea 2016;35(Suppl 1):S59–64.

[28] Gerber HP, McMurtry A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336–43.

[29] Sugioka K, Mishima H, Kodama A, et al. Regulatory mechanism of collagen degradation by keratocytes and corneal inflammation: the role of urokinase-type plasminogen activator. Cornea 2016;35(Suppl 1):S59–64.

[30] Aslan A, van Meurs M, Mower J, et al. Organ-specific differences in endothelial permeability-regulating molecular responses in mouse and human Sepsis. Shock 2017;48:69–77.

[31] Peng Y, Gao M, Jiang Y, et al. Angiogenesis inhibitor endostatin protects mice with sepsis from multiple organ dysfunction syndrome. Shock 2015;44:357–64.

[32] Sugio K, Mishima H, Kodama A, et al. Regulatory mechanism of collagen degradation by keratocytes and corneal inflammation: the role of urokinase-type plasminogen activator. Cornea 2016;35(Suppl 1):S59–64.

[33] Dinesh P, Rasool M. uPA/uPAR signaling in rheumatoid arthritis: shedding light on its mechanism of action. Pharmacol Res 2018;134:31–9.

[34] Lian S, Xia Y, Nguyen TT, et al. Docosahexaenoic acid inhibits tumor promoter-induced urokinase-type plasminogen activator receptor by suppressing PKD Delta- and MAPK-mediated pathways in ECV304 human endothelial cells. PLoS One 2016;11:e0163395.

[35] Jin T, Bokarewa M, Tarkowski A. Urokinase-type plasminogen activator, an endogenous antibiotic. J Infect Dis 2005;192:429–37.

[36] Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004;25:540–5.

[37] Yang K-Y, Liu K-T, Chen Y-C, et al. Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study. Crit Care 2011;15:R11.